Ionis widens eplontersen agreement with AstraZeneca; Inozyme looks to get $60M in public offering
AstraZeneca is paying $20 million to Ionis to gain commercialization rights in Latin America for a drug waiting for the FDA’s signoff.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
